XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 14 - Segments (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended June 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
United States		$	—			$	—			$	—			$	—
International			6,519				—				—				6,519
Grant and other revenue			51,007				—				—				51,007
Total revenue			57,526				—				—				57,526
Cost of revenue, excluding depreciation and amortization			473				—				—				473
Research and development expenses			1,636,691				87,297				—				1,723,988
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,001				1,230,894				1,233,895
Depreciation and amortization ⁽²⁾			6,041				—				15,730				21,771
Loss from operations ⁽³⁾			(1,585,679	)			(90,298	)			(1,246,624	)			(2,922,601	)
Other expense ⁽⁴⁾			—				—				(76,858	)			(76,858	)
Net loss			(1,585,679	)			(90,298	)			(1,323,482	)			(2,999,459	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	2,043,815			$	2,093,815
International			384,294				—				25,596				409,890
Capital expenditures			40,221				—				8,436				48,657

Three Months Ended June 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	13,063			$	—			$	—			$	13,063
Grant and other revenue			247,983				—				—				247,983
Total revenue			261,046				—				—				261,046
Research and development expenses			1,358,123				139,933				—				1,498,056
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				873				1,411,879				1,412,752
Depreciation and amortization ⁽²⁾			6,041				—				13,817				19,858
Loss from operations ⁽³⁾			(1,103,118	)			(140,806	)			(1,425,696	)			(2,669,620	)
Other expense ⁽⁴⁾			—				—				(4,420	)			(4,420	)
Net loss			(1,103,118	)			(140,806	)			(1,430,116	)			(2,674,040	)
Total assets, net of depreciation and amortization:
United States		$	269,464			$	—			$	10,811,515			$	11,080,979
International			199,741				—				590				200,331
Capital expenditures			—				—				2,707				2,707

Six Months Ended June 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
United States		$	—			$	—			$	—			$	—
International			6,519				—				—				6,519
Grant and other revenue			51,007				—				—				51,007
Total revenue			57,526				—				—				57,526
Cost of revenue, excluding depreciation and amortization			473				—				—				473
Research and development expenses			2,626,578				266,664				—				2,893,242
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,001				3,018,045				3,021,046
Depreciation and amortization ⁽²⁾			12,081				—				32,568				44,649
Loss from operations ⁽³⁾			(2,581,606	)			(269,665	)			(3,050,613	)			(5,901,884	)
Other income ⁽⁴⁾			—				—				(84,819	)			(84,819	)
Net loss			(2,581,606	)			(269,665	)			(3,135,432	)			(5,986,703	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	2,043,815			$	2,093,815
International			384,294				—				25,596				409,890
Capital expenditures			40,221				—				8,436				48,657

Six Months Ended June 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	35,549			$	—			$	—			$	35,549
Grant and other revenue			349,234				—				—				349,234
Total revenue			384,783				—				—				384,783
Research and development expenses			2,452,513				268,297				—				2,720,810
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				2,879				3,622,870				3,625,749
Depreciation and amortization ⁽²⁾			12,081				—				25,525				37,606
Loss from operations ⁽³⁾			(2,079,811	)			(271,176	)			(3,648,395	)			(5,999,382	)
Other income ⁽⁴⁾			—				—				358,450				358,450
Net loss			(2,079,811	)			(271,176	)			(3,289,945	)			(5,640,932	)
Total assets, net of depreciation and amortization:
United States		$	269,464			$	—			$	10,811,515			$	11,080,979
International			199,741				—				590				200,331
Capital expenditures			—				—				2,707				2,707